WASHINGTON (CN) - Companies making generic drugs must submit data for all tests done and relied upon when applying for approval by the FDA, including those with negative results, beginning July 15.
They also will have to report annually on all studies done or obtained after the generic drug has been released to the public.
Makers of generics generally may rely on studies done by the brand-name drug maker, but also must show that the generic is "biologically equivalent" to the brand-name drug, or, is of the same strength, goes into the body at the same rate, and is expected to have the same therapeutic effect.
Click the document icon on the front page for details and links to the regulations. The document icon under the "Yogurt Identity, Medicare & More" heading leads to other new regulations.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.
Additional Reads
-
Why executions by firing squad may be coming back in the US March 24, 2023 -
High court invited to tackle fairness for trans athletes March 15, 2023
-
-
Novo Nordisk plans price cuts for several insulins March 14, 2023